NL300889I2 - Trifluridine in combinatie met tipiracilhydrochloride - Google Patents
Trifluridine in combinatie met tipiracilhydrochloride Download PDFInfo
- Publication number
- NL300889I2 NL300889I2 NL300889C NL300889C NL300889I2 NL 300889 I2 NL300889 I2 NL 300889I2 NL 300889 C NL300889 C NL 300889C NL 300889 C NL300889 C NL 300889C NL 300889 I2 NL300889 I2 NL 300889I2
- Authority
- NL
- Netherlands
- Prior art keywords
- trifluridine
- combination
- ftd
- dose
- tipiracil hydrochloride
- Prior art date
Links
- KGHYQYACJRXCAT-UHFFFAOYSA-N tipiracil hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 KGHYQYACJRXCAT-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003962 trifluridine Drugs 0.000 title abstract 2
- 229960001740 tipiracil hydrochloride Drugs 0.000 title 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 title 1
- 239000012830 cancer therapeutic Substances 0.000 abstract 2
- 229940126585 therapeutic drug Drugs 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300889I1 NL300889I1 (nl) | 2017-08-14 |
| NL300889I2 true NL300889I2 (nl) | 2018-01-16 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300889C NL300889I2 (nl) | 2005-01-26 | 2017-08-08 | Trifluridine in combinatie met tipiracilhydrochloride |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (enExample) |
| JP (1) | JP5576591B2 (enExample) |
| KR (1) | KR101468216B1 (enExample) |
| AU (1) | AU2006209547C1 (enExample) |
| BE (1) | BE2017C028I2 (enExample) |
| CA (1) | CA2594713A1 (enExample) |
| CY (2) | CY2017029I2 (enExample) |
| DK (1) | DK1849470T4 (enExample) |
| ES (1) | ES2630002T5 (enExample) |
| FI (1) | FI1849470T4 (enExample) |
| FR (1) | FR17C1028I2 (enExample) |
| HU (2) | HUE033306T2 (enExample) |
| LT (2) | LT1849470T (enExample) |
| LU (1) | LUC00036I2 (enExample) |
| NL (1) | NL300889I2 (enExample) |
| PL (1) | PL1849470T5 (enExample) |
| PT (1) | PT1849470T (enExample) |
| RU (1) | RU2394581C2 (enExample) |
| SI (1) | SI1849470T2 (enExample) |
| TW (1) | TWI362265B (enExample) |
| WO (1) | WO2006080327A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| SI1849470T2 (sl) | 2005-01-26 | 2024-05-31 | Taiho Pharmaceutical Co., Ltd. | Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| US8536188B2 (en) | 2007-04-25 | 2013-09-17 | Cyclacel Limited | Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine |
| WO2009092601A1 (en) | 2008-01-25 | 2009-07-30 | Grünenthal GmbH | Pharmaceutical dosage form |
| NZ588863A (en) | 2008-05-09 | 2012-08-31 | Gruenenthal Chemie | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| CA2723944A1 (en) * | 2008-05-15 | 2009-11-19 | Jan Balzarini | Anti-cancer combination therapy |
| ES2718688T3 (es) | 2009-07-22 | 2019-07-03 | Gruenenthal Gmbh | Forma de dosificación resistente a la manipulación para opioides sensibles a la oxidación |
| JP5667183B2 (ja) | 2009-07-22 | 2015-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 加熱溶融押出成型した制御放出性投与剤型 |
| CN103269688A (zh) | 2010-09-02 | 2013-08-28 | 格吕伦塔尔有限公司 | 包含无机盐的抗破碎剂型 |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| EP2736495B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| NO2736497T3 (enExample) | 2011-07-29 | 2018-01-20 | ||
| ES2659264T3 (es) * | 2011-08-16 | 2018-03-14 | Taiho Pharmaceutical Co., Ltd. | Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS |
| TWI503122B (zh) * | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| AU2013233226B2 (en) | 2012-03-14 | 2016-05-19 | Nisshin Pharma Inc. | Sulfur amino acid-containing composition |
| TR201815502T4 (tr) | 2012-04-18 | 2018-11-21 | Gruenenthal Gmbh | Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu. |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| SG10201608469RA (en) | 2012-05-16 | 2016-11-29 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| WO2014157444A1 (ja) * | 2013-03-27 | 2014-10-02 | 大鵬薬品工業株式会社 | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 |
| EP2979701B1 (en) * | 2013-03-27 | 2020-08-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent including irinotecan hydrochloride hydrate |
| EP2998742A4 (en) * | 2013-05-17 | 2017-01-18 | Taiho Pharmaceutical Co., Ltd. | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased |
| MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| CN105682643B (zh) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型 |
| SMT202300167T1 (it) | 2013-09-06 | 2023-07-20 | Taiho Pharmaceutical Co Ltd | Agente antitumorale e potenziatore dell’effetto antitumorale |
| JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
| EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| JP2017516789A (ja) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
| HK1246173A1 (zh) | 2015-04-24 | 2018-09-07 | Grünenthal GmbH | 具有立即释放和对溶剂萃取的抗性的抗篡改剂型 |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US11612653B2 (en) | 2016-01-08 | 2023-03-28 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor agent containing immunomodulator, and antitumor effect potentiator |
| TWI791430B (zh) * | 2016-02-05 | 2023-02-11 | 日商大鵬藥品工業股份有限公司 | 針對具有重度腎功能障礙之癌症患者之治療方法 |
| WO2019124544A1 (ja) | 2017-12-22 | 2019-06-27 | 大鵬薬品工業株式会社 | トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法 |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU681321B2 (en) | 1995-03-29 | 1997-08-21 | Taiho Pharmaceutical Co., Ltd. | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
| AU699728B2 (en) * | 1996-09-24 | 1998-12-10 | Taiho Pharmaceutical Co., Ltd. | Cancerous metastasis inhibitors containing uracil derivatives |
| SI1849470T2 (sl) | 2005-01-26 | 2024-05-31 | Taiho Pharmaceutical Co., Ltd. | Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze |
-
2006
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en active Active
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en active Active
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es active Active
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja active Active
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko active Active
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300889I2 (nl) | Trifluridine in combinatie met tipiracilhydrochloride | |
| EP2444072A3 (en) | Non-mucoadhesive film dosage forms | |
| BR0312573A (pt) | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina | |
| WO2007056023A3 (en) | Thiazole inhibitors targeting resistant kinase mutations | |
| NO20065878L (no) | Terapeutiske forbindelser | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| WO2006056711A3 (fr) | Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire | |
| WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
| TW200716628A (en) | Novel compounds | |
| DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| WO2007046868A3 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
| MY140630A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| TW200504030A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| WO2006125194A3 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
| TW200626581A (en) | Compounds, compositions containing them, preparation thereof and uses thereof | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| TW200509909A (en) | Use of organic compounds | |
| BRPI0510820A (pt) | composição farmacêutica, forma unitária de dosagem e seus usos | |
| WO2005107768A3 (en) | Method for improving ventilatory efficiency | |
| ATE357220T1 (de) | Pharmazeutische zusammensetzung mit modifizierter freisetzung | |
| TW200626133A (en) | Oral medication for twice-daily administration |